<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:creator>De Prez, Vincent</dc:creator>
  <dc:creator>Jolidon, Vladimir</dc:creator>
  <dc:creator>Willems, Barbara</dc:creator>
  <dc:creator>Cullati, Stéphane</dc:creator>
  <dc:creator>Burton-Jeangros, Claudine</dc:creator>
  <dc:creator>Bracke, Piet</dc:creator>
  <dc:date>2020-06-01</dc:date>
  <dc:description xmlns:ns0="xml" ns0:lang="en">Cervical cancer screening (CCS) by means of Pap smears has led to a decrease in  cervical cancer incidence and mortality. In the absence of organized programmes,  CCS is opportunistic in Belgium and Switzerland. This might result in a high level of  CCS overuse, as screening practices do not conform to the recommended 3-yearly  screening interval and the target age-ranges (Belgium: 25–64, Switzerland: 20–70).  This study aimed to assess trends in CCS uptake and overuse in Belgium and  Switzerland and their social determinants, in the light of reimbursement initiatives,  which were implemented in both countries.Methods: Data from five waves of the  Belgian Health Interview Survey (1997–2013) (N=11 141) and Swiss Health Interview  Survey (1992–2012) (N=32 696) were used. We performed Poisson regressions to  estimate adjusted prevalence ratios (APR), controlled for socio-economic and socio- demographic characteristics and health status. CCS overuse was operationalized as  screening more than once every 3 years and screening above recommended age- range.Results: CCS uptake remained relatively stable over time, with a mean  coverage of 70.9% in Belgium and 73.1% in Switzerland. Educational and income  gradients were found in both countries. Concerning CCS overuse, women above  screening-eligible age showed consistently high screening rates, but screening within  the past year declined significantly in both countries, matching the temporal  implementation of the reimbursement initiatives.ConclusionsAlthough no increase in  CCS coverage could be established, CCS has become more efficient in both countries  as Pap smear overuse at the population level has declined after the implementation of  reimbursement measures tackling CCS overuse.</dc:description>
  <dc:format>application/pdf</dc:format>
  <dc:identifier>https://folia.unifr.ch/global/documents/308691</dc:identifier>
  <dc:identifier>https://folia.unifr.ch/documents/308691/files/cul_cco.pdf</dc:identifier>
  <dc:language>eng</dc:language>
  <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1093/eurpub/ckaa041</dc:relation>
  <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
  <dc:rights>License undefined</dc:rights>
  <dc:source>European Journal of Public Health. - 2020, vol. 30, no. 3, p. 552–557</dc:source>
  <dc:subject>info:eu-repo/classification/udc/61</dc:subject>
  <dc:title xmlns:ns1="xml" ns1:lang="en">Cervical cancer (over)screening in Belgium and Switzerland: trends and social inequalities</dc:title>
  <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
</oai_dc:dc>
